SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Press Releases
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
June 9, 2026
 · 
18 min read
Press Releases
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
June 3, 2026
 · 
20 min read
Press Releases
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
June 2, 2026
 · 
1 min read
Press Releases
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
June 1, 2026
 · 
15 min read
Press Releases
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
May 28, 2026
 · 
1 min read
Press Releases
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
May 27, 2026
 · 
17 min read
Press Releases
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2026
 · 
16 min read
Press Releases
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
May 6, 2026
 · 
22 min read
Press Releases
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update
April 30, 2026
 · 
1 min read
Press Releases
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
April 22, 2026
 · 
13 min read
Press Releases
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
April 15, 2026
 · 
14 min read
Press Releases
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
March 19, 2026
 · 
13 min read
Press Releases
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
March 9, 2026
 · 
16 min read
Press Releases
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
March 6, 2026
 · 
13 min read
Press Releases
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
March 2, 2026
 · 
6 min read
Press Releases
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
February 26, 2026
 · 
25 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS